CDXS
$23.50
Codexis
($.58)
(2.41%)
CDXS
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.18)
Revenue:  $23.15 Mil
Thursday
Feb 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, November 4, 2021

What do you expect when CDXS reports earnings?
Beat
Meet
Miss

Where is CDXS's stock price going from here?
Up
Flat
Down
Stock chart of CDXS
Analysts
Summary of analysts' recommendations for CDXS
Score
Grade
Pivots
Resistance
$25.56
$24.89
$24.19

$23.52

Support
$22.82
$22.15
$21.45
Tweet
Growth
Description
Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. Codexis? proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.
Peers
IncyteExact SciencesExelixisCharles River Laboratories InternationalCoherus Biosciences